Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) and Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares Contineum Therapeutics and Amneal Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Contineum Therapeutics | N/A | N/A | -$59.98 million | ($1.77) | -4.98 |
| Amneal Pharmaceuticals | $3.20 billion | 2.32 | $72.06 million | $0.42 | 50.75 |
Amneal Pharmaceuticals has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Contineum Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Contineum Therapeutics and Amneal Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Contineum Therapeutics | 1 | 2 | 2 | 0 | 2.20 |
| Amneal Pharmaceuticals | 0 | 2 | 8 | 0 | 2.80 |
Contineum Therapeutics presently has a consensus price target of $21.40, indicating a potential upside of 142.60%. Amneal Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 7.91%. Given Contineum Therapeutics’ higher possible upside, research analysts plainly believe Contineum Therapeutics is more favorable than Amneal Pharmaceuticals.
Institutional & Insider Ownership
31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Contineum Therapeutics and Amneal Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Contineum Therapeutics | N/A | -25.48% | -24.28% |
| Amneal Pharmaceuticals | 4.17% | 283.50% | 7.79% |
Summary
Amneal Pharmaceuticals beats Contineum Therapeutics on 12 of the 13 factors compared between the two stocks.
About Contineum Therapeutics
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory and fibrotic diseases. The company is based in San Diego, California, and was previously known as Pipeline Therapeutics. Its development programs include PIPE-307, an investigational M1 receptor antagonist being studied for neurological conditions, including relapsing-remitting multiple sclerosis. Contineum is also developing PIPE-791, an investigational LPA1 receptor antagonist for fibrotic lung diseases and related conditions.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
